Pliant Therapeutics, Inc.
NASDAQ:PLRXBiotechnology
-$0.04 today
- Market cap
- $50.14M
- Beta
- 1.21
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.83
Volume 0.15M
Average 0.49M
PLRX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Pliant Therapeutics, Inc.NASDAQ: PLRX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$19.78M, compared with -$54.92M a year earlier. Trailing-twelve-month EBITDA was -$107.98M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of -$83.83M (+42.2%) for the fiscal year ending Dec 2026, a step up from the +29.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$19.78M+14.3% QoQ
- Last fiscal yearDec 2025
- -$145.09M+29.3% YoY
- LTMMar 2026
- -$107.98M+49.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +64.0% | — | — |
| 1 year | +29.3% | +42.2% | +12.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (145.09M) USD
- Year-over-year change
- +29.3%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (145.09M) | +29.3% |
| FY2024 | 2024-12-31 | (205.16M) | -29.7% |
| FY2023 | 2023-12-31 | (158.23M) | -33.1% |
| FY2022 | 2022-12-31 | (118.85M) | -24.2% |
| FY2021 | 2021-12-31 | (95.73M) | — |
EBITDA vs competitors
How PLRX compares with its peers on the latest reported figures
- PLRX's LTM Mar 2026 EBITDA of -$107.98M is the 8th highest of the 10 companies compared; the peer median is -$84.44M.
- Its year-over-year change of +49.6% is the highest of 10, against a peer median of -18.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$21.1M | -18.3% | — | 265.8% | |
| LTM Mar 2026 | -$24M | +7.8% | — | 337.0% | |
| LTM Mar 2026 | -$29.2M | -21.6% | — | 21792.5% | |
| LTM Mar 2026 | -$50.64M | -7.0% | — | 32.2% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$84.44M | -35.4% | — | — |
| LTM Mar 2026 | -$106.12M | +42.0% | — | 106.5% | |
| LTM Mar 2026 | -$106.88M | -21.2% | — | — | |
| LTM Mar 2026 | -$107.98M | +49.6% | — | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | -$115.78M | -490.7% | — | — |
| LTM Mar 2026 | -$130.98M | +37.9% | — | — | |
| Peer median (excluding PLRX) | -$84.44M | -18.3% | — | 265.8% | |
Competitors are the stored peer set for PLRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.57M | 9.69M | 1.58M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.7M |
| Gross Profit | 7.57M | 9.69M | 1.58M | 0 | (1.7M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 77.55M | 96.94M | 127.8M | 169.31M | 109.16M |
| Selling, General & Admin | 27.56M | 39.95M | 57.93M | 59.06M | 47.22M |
| Operating Expenses | 105.11M | 136.89M | 185.73M | 228.37M | 148.38M |
| Depreciation & Amortization | 1.54M | 3.68M | 1.84M | 2.13M | 1.7M |
| EBITDA | (95.73M) | (118.85M) | (158.23M) | (205.16M) | (145.09M) |
| EBITDA Margin | -1264.2% | -1227.1% | -10014.4% | — | — |
| Operating Income | (97.54M) | (127.2M) | (184.15M) | (228.37M) | (150.07M) |
| Operating Margin | -1288.1% | -1313.4% | -11654.7% | — | — |
| Interest Income | 272K | 4.67M | 24.08M | 21.09M | 0 |
| Interest Expense | 0 | 791K | 1.27M | 3.02M | 2.56M |
| Other Income / Expenses | 272K | 3.88M | 22.81M | 18.06M | 729K |
| Income Before Tax | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Pre-Tax Margin | -1284.5% | -1273.3% | -10211.1% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (97.26M) | (123.32M) | (161.34M) | (210.3M) | (149.34M) |
| Net Margin | -1284.5% | -1273.3% | -10211.1% | — | — |
| EPS (Basic) | (2.71) | (2.94) | (2.75) | (3.47) | (2.43) |
| EPS (Diluted) | (2.71) | (2.94) | (2.75) | (3.47) | (2.43) |
| Weighted Avg Shares | 35.85M | 42.02M | 58.72M | 60.54M | 61.37M |
| Weighted Avg Shares (Diluted) | 35.85M | 42.02M | 58.72M | 60.54M | 61.37M |
Pliant Therapeutics, Inc.
NASDAQ:PLRX
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.